From the Journals

saRNA Injection Targets Cardiac Injury

Preclinical study shows saRNA therapy improved cardiac function and reduced infarct size after myocardial infarction

  • March 17, 2026

  • 2 min

Share

  • 1

    saRNA therapy supports heart recovery post-myocardial infarction.

  • 2

    Delivered via a single intramuscular injection.

  • 3

    Sustained production of atrial natriuretic peptide for over 4 weeks.

  • 4

    Improved cardiac function and reduced fibrosis in preclinical models.

  • 5

    Promotes healing mechanisms in the heart.

  • 6

    Avoids invasive delivery methods.

  • 7

    Future study will focus on safety and human trials.

Original Source(s)

saRNA Injection Targets Cardiac Injury

  • March 17, 2026

Related Content

Premature Menopause Tied to Higher Lifetime CHD Risk

Lifetime risk estimates evaluated by menopause timing.

Proteomic Profiling Defines Vascular Cell States

Label-free LC–MS profiles nearly 5,000 cells, resolving smooth muscle subtypes and disease-associated phenotypes 

  • March 18, 2026

  • 2 min
Guideline Reclassifies 11% of Patients With Stage 1 Hypertension

Risk-based criteria reduced automatic treatment eligibility among older adults without high-risk comorbidities.